BrainStorm announces Nasdaq delisting and transition to OTCQB
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 17 2025
0mins
Delisting Notification: BrainStorm Cell Therapeutics has received a notification from Nasdaq that its common stock will be delisted due to non-compliance with the minimum shareholder equity requirement, effective July 18.
Transition to OTCQB: The company has secured approval to have its shares quoted on the OTCQB Venture Market under the same symbol, BCLI, starting July 18 or shortly thereafter.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
